Recursion Pharmaceuticals projects $100M synergies in 2025 amid advancing pipeline and partnerships

Feb. 28, 2025 1:17 PM ETRecursion Pharmaceuticals, Inc. (RXRX) StockAI-Generated Earnings Calls Insights
(6min)

Earnings Call Insights: Recursion Pharmaceuticals (NASDAQ:RXRX) Q4 2024

Management View

  • CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a CDK7 inhibitor, demonstrated tumor reduction in a dose-escalation phase, while
Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Recommended For You

More Trending News

About RXRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RXRX--
Recursion Pharmaceuticals, Inc.